Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Diaz, Asuncion ^a   Diez, Mercedes ^b   Bleda, Maria J ^a   Aldamiz, Mikel ^c   Camafort, Miguel ^d   Camino, Xabier ^e   Cepeda, Concepcion ^f   Costa, Asuncion ^f   Ferrero, Oscar ^g   Geijo, Paloma ^h   Iribarren, Jose A ^e   Moreno, Santiago ⁱ   Moreno, Maria E ⁱ   Labarga, Pablo ^j   Pinilla, Javier ^j   Portu, Joseba ^c   Pulido, Federico ^f   Rosa, Carmen ^h   Santamaría, Juan M ^g   Telenti, Mauricio ^k   Trapiella, Luis ^k   Trastoy, Monica ^l   Viciana, Pompeyo ^l   more..

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

^b Ministerio de Sanidad Y Consumo   (Spain)

^c HOSPITAL TXAGORRITXU   (Spain)

^d INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^e Hospital Nuestra Senora de Aranzazu   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL DE BASURTO   (Spain)

^h HOSPITAL VIRGEN DE LA LUZ   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j HOSPITAL SAN PEDRO   (Spain)

^k HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; FEMALE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ABUSE; LATENT TUBERCULOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; SHORT COURSE THERAPY; SPAIN; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULIN TEST; MIDDLE AGED; PROSPECTIVE STUDY; STATISTICS;

ADULT; ANTITUBERCULAR AGENTS; FEMALE; HIV INFECTIONS; HUMANS; LATENT TUBERCULOSIS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 77956471709     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-267     Document Type: Article

References (30)

1. Diez M, Huerta C, Moreno T, Caloto T, Guerra D, Pozo F, Alcaide J, Castells C, Cardenal JI, Domínguez A, Gayoso P, Gutiérrez G, López MJ, Muñoz F, Navarro C, Picó M, Quirós JR, Robles F, Sánchez JM, Vanaclocha H, Vega T, . Multicentre Project for Tuberculosis Research (MPTR) Study Group Tuberculosis in Spain: epidemiological pattern and clinical practice. Int J Tuberc Lung Dis 2002, 6:295-300. Multicentre Project for Tuberculosis Research (MPTR) Study Group.
2. Muga R, Ferreros I, Langohr K, de Olalla PG, Del Romero J, Quintana M, Alastrue I, Belda J, Tor J, Pérez-Hoyos S, Del Amo J, . Spanish Multicenter Study Group of Seroconverters (GEMES) Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS 2007, 21:2521-2527. 10.1097/QAD.0b013e3282f1c933, 18025889, Spanish Multicenter Study Group of Seroconverters (GEMES).
3. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007, 21:1441-1448. 10.1097/QAD.0b013e328216f441, 17589190.
4. Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fätkenheuer G, Sterne JA, . Antiretroviral Therapy Cohort Collaboration Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005, 41:1772-1782. 10.1086/498315, 16288403, Antiretroviral Therapy Cohort Collaboration.
5. Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Rickenbach M, Furrer H, . Swiss HIV Cohort Study Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007, 44:94-102. 10.1086/510080, 17143823, Swiss HIV Cohort Study.
6. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004, 1:CD000171.
7. Churchyard GJ, Scano F, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007, 196(Suppl 1):S52-62. 10.1086/518662, 17624827.
8. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007, 24:e238.
9. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008, 12:1235-1254.
10. Antonucci G, Girardi E, Raviglione M, Vanacore P, Angarano G, Chirianni A, Pagano G, Suter F, Lauria FN, Ippolito G. Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study. GISTA (Gruppo Italiano di Studio Tubercolosi e AIDS). Eur Respir J 2001, 18:369-375. 10.1183/09031936.01.00087901, 11529298.
11. Diaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, Iribarren JA, Moreno S, Moreno ME, Labarga P, Pinilla J, Portu J, Pulido F, Rosa C, Santamaría JM, Telenti M, Trapiella L, Trastoy M, Viciana P. Factores asociados a la no realización de la prueba de la tuberculina en una cohorte de pacientes VIH positivos [Factors related to non-prescription of tuberculin skin testing in a cohort of HIV-infected people]. Enferm Infecc Microbiol Clin 2010, 28:215-21. 10.1016/j.eimc.2009.06.008, 19683364.
12. Diez M, Diaz A, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, Iribarren JA, Moreno S, Moreno ME, Labarga P, Pinilla J, Portu J, Pulido F, Rosa C, Santamaria JM, Telenti M, Trapiella L, Trastoy M, Viciana P. Prevalence of M. tuberculosis infection and tuberculosis disease among HIV-infected people in Spain. Int J Tuberc Lung Dis 2007, 11:1196-1202.
13. Berenguer J, Laguna F, López-Aldeguer J, Moreno S, Arribas JR, Arrizabalaga J, Baraia J, Casado JL, Cosín J, Polo R, González-García J, Iribarren JA, Kindelán JM, López-Bernaldo de Quirós JC, López-Vélez R, Lorenzo JF, Lozano F, Mallolas J, Miró JM, Pulido F, Ribera E. Prevención de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el VIH. Recomendaciones de GESIDA/Plan Nacional sobre el Sida [Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan recommendations]. Enferm Infecc Microbiol Clin 2004, 22:160-176. 10.1157/13058025, 14987537.
14. Ministerio de Sanidad y Consumo. Fondo de Investigación Sanitaria Consenso nacional para el control de la tuberculosis [National consensus on the control of tuberculosis in Spain]. Med Clin (Barc) 1992, 98:24-31. Ministerio de Sanidad y Consumo. Fondo de Investigación Sanitaria.
15. Hosmer DW, Lemeshow S. Applied Logistic Regression 2000, New York: Wiley-Interscience, 2.
16. McCullagh P, Nelder J. Generalized Linear Models 1989, London: Chapman and Hall, 2.
17. Narita M, Kellman M, Franchini DL, McMillan ME, Hollender ES, Ashkin D. Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection. The 2-year experience of a comprehensive community-based program in Broward County, Florida. Chest 2002, 122:1292-1298. 10.1378/chest.122.4.1292, 12377855.
18. Martínez Alfaro EM, Cuadra F, Solera J, Maciá MA, Geijo P, Sánchez Martínez PA, Rodríguez Zapata M, Largo J, Sepúlveda MA, Rosa C, Sánchez L, Espinosa A, Mateos F, Blanch JJ. Evaluación de dos pautas de quimioprofilaxis tuberculosa en pacientes infectados por el virus de la inmunodeficiencia humana [Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus]. Med Clin (Barc) 2000, 115:161-165.
19. Rivero A, López-Cortés L, Castillo R, Verdejo J, García MA, Martínez-Marcos FJ, Díez F, Escribano JC, Canueto J, Lozano F, Pasquau J, Hernández JJ, Márquez M, Kindelán JM, . Grupo Andaluz para el estudio de las Enfermedades Infecciosas (GAEI) Ensayo clínico aleatorizado para evaluar tres pautas cortas de tratamiento de la infección latente tuberculosa en pacientes infectados por el VIH [Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients]. Enferm Infecc Microbiol Clin 2007, 25:305-310. 10.1157/13102265, 17504683, Grupo Andaluz para el estudio de las Enfermedades Infecciosas (GAEI).
20. Pina-Gutiérrez JM, Ferrer-Traid A, Arias C, Sala-Farré MR, López-Sanmartín JL. Cumplimiento y efectividad del tratamiento de la infección tuberculosa con isoniazida durante 9 meses en una cohorte de 755 pacientes [Adherence and effectiveness of the treatment of latent tuberculosis infection with isoniazid for 9 months in a cohort of 755 patients]. Med Clin (Barc) 2008, 130:165-171. 10.1157/13116320, 18341830.
21. Sackoff JE, Torian LV, Frieden TR, Brudney KF, Menzies IB. Purified protein derivative testing and tuberculosis preventive therapy for HIV-infected patients in New York City. AIDS 1998, 12:2017-2023. 10.1097/00002030-199815000-00013, 9814870.
22. Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med 2006, 174:717-721. 10.1164/rccm.200510-1667OC, 16809632.
23. García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002, 30:105-110. 10.1097/00126334-200205010-00014, 12048370.
24. Gourevitch MN, Hartel D, Selwyn PA, Schoenbaum EE, Klein RS. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. AIDS 1999, 13:2069-2074. 10.1097/00002030-199910220-00009, 10546859.
25. Portilla J, Jordá P, Esteban J, Sánchez-Payá J, Merino E, Boix V, . Grupo de Estudio Protocolo-INH Tratamiento directamente observado de la infección tuberculosa latente: estudio comparativo de dos pautas con isoniacida [Directly observed treatment of latent tuberculosis infection: comparative study of two isoniazid regimens]. Enferm Infecc Microbiol Clin 2003, 21:293-295. 10.1157/13048576, 12809583, Grupo de Estudio Protocolo-INH.
26. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geiter L, Johnson E, Huebner R, Boulos R, Chaisson RE. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998, 351:786-792. 10.1016/S0140-6736(97)06532-X, 9519950.
27. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, Nyirenda O, Luo N, Pobee J, Elliott AM, McAdam KP, Porter JD. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998, 12:2447-2457. 10.1097/00002030-199818000-00014, 9875583.
28. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, Barry MA, O'Brien RJ. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 2000, 283:1445-1450. 10.1001/jama.283.11.1445, 10732934.
29. Centers for Disease Control and Prevention (CDC); American Thoracic Society Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep 2003, 52:735-739. Centers for Disease Control and Prevention (CDC); American Thoracic Society.
30. Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR, . Tuberculosis Epidemiologic Studies Cosortium The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006, 173:927-931. 10.1164/rccm.200510-1563OC, 16424442, Tuberculosis Epidemiologic Studies Cosortium.